Acute myeloid leukemia targets for bispecific antibodies

作者：Hoseini S S; Cheung N K

来源：Blood Cancer Journal, 2017, 7(2): e522.

DOI：10.1038/bcj.2017.2

<jats:title>Abstract</jats:title>
<jats:p>Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behind. Bispecific antibodies can redirect polyclonal effector cells to engage chosen targets on leukemia blasts. When the effector cells are natural-killer cells, both antibody-dependent and antibody-independent mechanisms could be exploited. When the effectors are T cells, direct tumor cytotoxicity can be engaged followed by a potential vaccination effect. In this review, we summarize the AML-associated tumor targets and the bispecific antibodies that have been studied. The potentials and limitations of each of these systems will be discussed.</jats:p>

• 出版日期2017-2